{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:37:13Z","timestamp":1790753833508,"version":"4.1.0"},"reference-count":15,"publisher":"American Association for Cancer Research (AACR)","issue":"1","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Summary:<\/jats:title><jats:p>In this issue of Cancer Discovery, Yap and colleagues demonstrate in a phase I trial enrolling 22 patients diagnosed with advanced solid tumors that BAY 1895344, a new potent and specific ATR inhibitor, is safe and able to induce durable responses in ATM-deficient tumors. This compelling clinical activity paves the way for innovative combination regimens that rely on exploitation of DNA damage response defects in cancer.<\/jats:p><jats:p>See related article by Yap et al., p. 80.<\/jats:p><\/jats:sec>","DOI":"10.1158\/2159-8290.cd-20-1354","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T09:35:54Z","timestamp":1609925754000},"page":"14-16","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["ATR Inhibition as an Attractive Therapeutic Resource against Cancer"],"prefix":"10.1158","volume":"11","author":[{"given":"Antoine","family":"Italiano","sequence":"first","affiliation":[{"name":"Early Phase Trials Unit, Institut Bergoni\u00e9, Bordeaux, France. DITEP, Gustave Roussy, Villejuif, France. University of Bordeaux, Bordeaux, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"key":"2022060622305594300_bib1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0955-0674(00)00201-5","article-title":"DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme?","volume":"13","author":"Durocher","year":"2001","journal-title":"Curr Opin Cell Biol"},{"key":"2022060622305594300_bib2","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1140321","article-title":"ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage","volume":"316","author":"Matsuoka","year":"2007","journal-title":"Science"},{"key":"2022060622305594300_bib3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.stem.2007.03.002","article-title":"Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss","volume":"1","author":"Ruzankina","year":"2007","journal-title":"Cell Stem Cell"},{"key":"2022060622305594300_bib4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1172\/JCI58928","article-title":"Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR","volume":"122","author":"Schoppy","year":"2012","journal-title":"J Clin Invest"},{"key":"2022060622305594300_bib5","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/ng.420","article-title":"A mouse model of ATRSeckel shows embryonic replicative stress and accelerated aging","volume":"41","author":"Murga","year":"2009","journal-title":"Nat Genet"},{"key":"2022060622305594300_bib6","doi-asserted-by":"crossref","first-page":"37139","DOI":"10.1074\/jbc.M307088200","article-title":"Caffeine inhibits checkpoint responses without inhibiting the ataxia telangiectasia-mutated (ATM) and ATM- and Rad3-related (ATR) protein kinases","volume":"278","author":"Cortez","year":"2003","journal-title":"J Biol Chem"},{"key":"2022060622305594300_bib7","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.cell.2006.03.035","article-title":"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling","volume":"125","author":"Knight","year":"2006","journal-title":"Cell"},{"key":"2022060622305594300_bib8","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1093\/nar\/gkp593","article-title":"Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response","volume":"37","author":"Nishida","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"2022060622305594300_bib9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov"},{"key":"2022060622305594300_bib10","doi-asserted-by":"crossref","first-page":"7445","DOI":"10.1073\/pnas.95.13.7445","article-title":"Protein kinase mutants of human ATR increase sensitivity to UV and ionizing radiation and abrogate cell cycle checkpoint control","volume":"95","author":"Wright","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060622305594300_bib11","doi-asserted-by":"crossref","first-page":"32396","DOI":"10.18632\/oncotarget.6136","article-title":"Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition","volume":"6","author":"Middleton","year":"2015","journal-title":"Oncotarget"},{"key":"2022060622305594300_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","article-title":"The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models","volume":"19","author":"Wengner","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"2022060622305594300_bib13","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(20)30180-7","article-title":"Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Konstantinopoulos","year":"2020","journal-title":"Lancet Oncol"},{"key":"2022060622305594300_bib14","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2019-272","article-title":"Synergistic activity of the ATR inhibitor BAY1895344 in combination with immune checkpoint inhibitors in preclinical tumor models [abstract]","volume-title":"Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29\u2013Apr 3; Atlanta, GA","author":"Wengner","year":"2019"},{"key":"2022060622305594300_bib15","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1158\/1538-7445.AM2019-2269","article-title":"Abstract 2269: ATR inhibitor M6620 enhances anti-tumor efficacy of the combination of the anti-PD-L1 antibody avelumab with platinum-based chemotherapy","volume":"79","author":"Alimzhanov","year":"2019","journal-title":"Cancer Res"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/11\/1\/14\/1818666\/14.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/11\/1\/14\/1818666\/14.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T19:01:07Z","timestamp":1670698867000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/11\/1\/14\/2750\/ATR-Inhibition-as-an-Attractive-Therapeutic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,6]]},"published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-20-1354","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,1]]}}}